Literature DB >> 12777867

Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation.

Markus Ditschkowski1, Hermann Einsele, Rainer Schwerdtfeger, Donald Bunjes, Rudolf Trenschel, Dietrich W Beelen, Ahmet H Elmaagacli.   

Abstract

Because causes of inflammatory bowel disease (IBD) remain obscure and a curative therapy is still lacking, the influence of stem-cell transplantation (SCT) on IBD is of major interest. We retrospectively analyzed the course of seven patients with Crohn's disease and four patients with idiopathic ulcerative colitis who underwent allogeneic SCT between July 1994 and August 2002 for acute and chronic myeloid leukemia and myelodysplastic syndrome. After a median follow-up of 34 months posttransplantation, 10 patients are alive. None of the patients showed IBD activity after SCT, except one patient with mild persistent symptoms of Crohn's disease early after transplant. Colonoscopy after complete discontinuation of prophylactic posttransplant immunosuppression revealed no pathologic findings. These observations imply that host immune dysregulation plays a central role in the perpetuation of IBD. It may be influenced by the implementation of a new allogeneic immune system resulting from the transplantation of hematopoietic stem cells.

Entities:  

Mesh:

Year:  2003        PMID: 12777867     DOI: 10.1097/01.TP.0000062540.29757.E9

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  28 in total

Review 1.  The immunomodulatory properties of mesenchymal stem cells: implications for surgical disease.

Authors:  Brent R Weil; Mariuxi C Manukyan; Jeremy L Herrmann; Aaron M Abarbanell; Jeffrey A Poynter; Yue Wang; Daniel R Meldrum
Journal:  J Surg Res       Date:  2010-08-06       Impact factor: 2.192

2.  Complete resolution of severe ulcerative colitis after haploidentical hematopoietic stem cell transplantation followed by post-transplant high-dose cyclophosphamide.

Authors:  A Unnikrishnan; S C Glover; O Norkina; J R Wingard; M Norkin
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

Review 3.  Use of mesenchymal stem cells (MSC) in chronic inflammatory fistulizing and fibrotic diseases: a comprehensive review.

Authors:  Jan Voswinkel; Sabine Francois; Jean-Marc Simon; Marc Benderitter; Norbert-Claude Gorin; Mohamad Mohty; Loïc Fouillard; Alain Chapel
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

4.  Inflammatory bowel disease after allogeneic stem cell transplantation.

Authors:  I Boussen; H Sokol; S Aractingi; O Georges; N Hoyeau-Idrissi; J P Hugot; M Mohty; M T Rubio
Journal:  Bone Marrow Transplant       Date:  2015-06-08       Impact factor: 5.483

Review 5.  Intestinal stem cells and epithelial-mesenchymal interactions in the crypt and stem cell niche.

Authors:  Anisa Shaker; Deborah C Rubin
Journal:  Transl Res       Date:  2010-07-03       Impact factor: 7.012

Review 6.  Hematopoietic cell transplantation for Crohn's disease; is it time?

Authors:  Y Leung; M Geddes; J Storek; R Panaccione; P L Beck
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

Review 7.  Therapy with stem cells in inflammatory bowel disease.

Authors:  María Del Pilar Martínez-Montiel; Gonzalo Jesús Gómez-Gómez; Ana Isabel Flores
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

Review 8.  Stem cells as a potential future treatment of pediatric intestinal disorders.

Authors:  Troy A Markel; Paul R Crisostomo; Tim Lahm; Nathan M Novotny; Frederick J Rescorla; Joseph Tector; Daniel R Meldrum
Journal:  J Pediatr Surg       Date:  2008-11       Impact factor: 2.545

9.  Comparison of the population capacity of hematopoietic and mesenchymal stem cells in experimental colitis rat model.

Authors:  Yaming Wei; Yuqiang Nie; Jieying Lai; Yu-Jui Yvonne Wan; Yuyuan Li
Journal:  Transplantation       Date:  2009-07-15       Impact factor: 4.939

Review 10.  Gastro-intestinal autoimmunity: preclinical experiences and successful therapy of fistulizing bowel diseases and gut Graft versus host disease by mesenchymal stromal cells.

Authors:  Jan Voswinkel; Sabine Francois; Norbert-Claude Gorin; Alain Chapel
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.